About
Michael Grissinger joined Adicet Bio's board in April 2025. He spent 22 years at Johnson & Johnson before retiring in 2018, serving in senior roles including Vice President and Head of Worldwide Pharmaceutical Licensing and Vice President and Head of Worldwide Pharmaceutical Corporate Development and M&A, and leading the Immunology Therapeutic Area Business Development and Licensing Group.
Prior to Johnson & Johnson he spent 12 years at Ciba-Geigy AG in finance, marketing and business development roles. He holds a B.Sc. in Chemistry from Juniata College and an MBA from Temple University's Fox School of Business.
Roles
Adicet Bio, Inc.
Director · Current role
2025–present
Johnson & Johnson
VP & Head of Worldwide Pharmaceutical Licensing; VP & Head of Worldwide Pharmaceutical Corporate Development and M&A · Spent 22 years at the company and retired in 2018; also led the Immunology Therapeutic Area Business Development and Licensing Group.
—
Ciba-Geigy AG
Finance, marketing and business development roles · Spent 12 years at the company prior to joining Johnson & Johnson.
—
Akari Therapeutics, Plc
Board member
2018-2024
resTORbio
Board member · Served from November 2018 until the completion of the merger in September 2020.
2018-2020
External Roles
Aprea Therapeutics, Inc.
Board member
—
Envisagenics, Inc.
Board member
—
AnaCardio AB
Board member
—
NephroDI Therapeutics, Inc.
Board member
—
Director Compensation
FY 2025
Fees earned or paid in cash
$31,772